The imipenem/cilastatin constitutes a broad spectrum /Mactam antibiotic formulation, especially used in pre and post-operatory treatments for transplanted or drug-immunosuppresedpatients. The effect of the dose and the duration of the treatment with imipenem/cilastatin on someparameters of natural immunity in BALB/cmice were examined. The treatment by intraperitoneal route with i or 2 g/70 kg/day during 7 days did not alter significantly the parameters tested, whereas the greater dose used (4 g/70 kg/day) had an inhibitory effect on peritoneal cell counts and phagocytic activity, as well as it caused an increase on IL-1 production and natural killer activity. The greater stimulating effect of innate immunity was obtained with the lowest imipenem/cilastatin dose used (0.5 g/70 kg/day). Since this antibiotic apparently does not impair the studied innate immune responses at 1 or 2 g/70kg/day, it seems to be especially suited for the therapy of systemic bacterial infections in immunocompromisedpatients.
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Antibiotics have biological properties other than direct antimicrobial activity. These include interactions and alterations in the cellular and/or humoral immune functions of the patients1~7).
The concept of immune response modifiers applied to antibacterial agents has arised recently, and it is a subject of growing research8~1 1}. Current investigations attempt to describe the immunological profiles of the new antimicrobial agents12~14), as well as avoiding the use of those having immunosuppresing activity on patients with any immunological deficiency1 5' 1 6).
The state of the nonspecific host defense system is important for the outcome of antimicrobial chemotherapy. Moreover, the effect of antibiotics on phagocytic function is of potential importance since these agents The preincubation of humangranulocytes with imipenem induces an increase ofadherence28) and chemotaxis28 '22) , but it does not influence the level of cellular activation measured by chemiluminescence28 '29) , opsonization, phagocytosis and the candidicide index22). The effects of intramuscular administration of imipenem and cilastatin on the phagocytic activity of murine peritoneal macrophages have also been examined by Nunez et al.30 In this study, we have investigated the influence of the dose and the duration of the treatment with imipenem/ cilastatin on several parameters of nonspecific immunity in mice.
Materials and Methods
Animals Six-to eight-week-old male BALB/c mice were used for the experiments.
They were maintained under pathogen-free conditions, with free access to food and water.
Antibiotic Regimen
The combination imipenem/eilastatin (I/C) was pro- (5-amino-2,3-dehydro-l ,4-phthalazinedione) in PBS at a concentration of 100 /ig/ml were added. The chemiluminescence mixtures were incubated for 2 minutes at 37°C and disposed in scintillation vials. The phagocytic activity of peritoneal cells was measured by photon emission 
Interleukin-1 (IL-1) Assay
The thymocyte co-stimulation bioassay was used for the measurement of soluble IL-1 according to the technique described by Muegge and Durum32). Briefly, the peritoneal cells were adjusted to a concentration of 2x 106cells/ml with complete medium. One ml of the cell suspensions was added to 35-mm-diameter plastic Petri dishes, as well as 1ml of Escherichia coli lipopolysaceharide (LPS; Sigma) at a concentration of 20jUg/ml. Thus, the final concentrations in the dishes were 106cells/ml and 10/ig/ml LPS. The mixtures were incubated for 24 hours at 37°G in 5% CO2, and finally supernatants were collected and stored at -80°C until quantitative assay. Thymus from 6-to 8-week-old mice were aseptically removed and homogenized in sterile HBSS. Thymocytes were washed twice by eentrifugation at 200 x g and 4°C for 10 minutes with HBSS, and finally resuspended in complete medium with 10^g/ml Phytohemagglutinin (PHA; Sigma). Cell suspensions were adjusted to a concentration of 107 cells/ml. IL-1 test samples were serially diluted 5-fold in complete mediumwithout PHA. 96-well flat-bottom microtiter plates received lOO' /il of thymocyte suspension and 100^1 of diluted samples per well. The plates were incubated for 48 hours at 37°C in 5%CO2. Cellular proliferation was measured by colorirnetric reading of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction as described by Mosmann33). along with 1ml of plasma clot medium (25% pool of human plasma + 75%complete medium). Finally, 40ju\ of calcium chloride (55mg/ml) were added directly to the petri dishes in order to obtain the plasma clot. After ascertaining the homogeneous dispersion of the cells, the dishes were incubated at 37°C in a 5% CO2atmosphere.
Four days later, clonal scoring was performed using an inverted microscope. Only clones with more than eight cells were counted, and the percentage of cloning inhibition was calculated, taking control experiments as maximumcell proliferation (100%).
Statistics
The differences between treated and control groups were analyzed by using Student's t-test. A P value of less than 0.05 was considered significant.
Results
Effect of I/C on Peritoneal Cell Counts Wechecked the peritoneal cell (PC) counts to determine the possible presence of an inflammatory reaction caused by the I/C treatment that mayexplain an alteration on the cellular activity of peritoneal leukocytic cells. As shownin Table 1 , two different behaviours were obtained in mice treated with I/C depending on the dispensed dose. Thus, treatment with 4g/70kg/day induced a decrease in PC counts with regard to that obtained in untreated control mice (P<0.05).
On the other hand, treatment with 0.5 g/70kg/day induced a Effect of I/C on Phagocytic Activity Because phagocytic activity is an important antibacterial mechanism of the natural immuneresponse, we examined the effect of I/C on the phagocytic cell activity, determined by CL. The results are shown in Table 2 ; the higher dose tested (4 g/70 kg/day) induced a pronounced suppression of peritoneal cell CL (P<0.05). In mice receiving 0.5g/70kg/day for 7 days, or with prolonged therapy at 2g, CL values were increased by more than 100% with regards to the control group (P<0.05 and P< 0.01, respectively).
Effect of I/C on IL-1 Production In order to examinethe effect of I/C treatment on the VOL.50 NO.6 THE JOURNAL OF ANTIBIOTICS cytokine production by peritoneal cells, we tested the production of IL-1 by peritoneal leukocytes. In previous assays, it was established that the greater proliferative capacity of thymocytes was obtained with the 1 :4 dilution of samples from peritoneal macrophage cultures. Thus, the results summarized in Table 3 Effect of I/C Treatment on Natural Killer Activity In order to examine the NKactivity of mononuclear splenic cells that, together with phagocytes, play a fundamental role in the cellular mechanisms of the natural immuneresponse, we tested the cytotoxic activity from splenic mononuelear leukocytes against K562cell line. As shown in fluenced its effect on the tested parameters. Obviously, this regime of treatment cannot completely imitate therapeutic conditions; particularly since a faster metabolism of the drug can be expected in mice29). Thus, it seems that the pharmacological exposure of the mice to the antibiotic used in these experiments was even less than under maximaltherapeutic conditions. Our results showed a dose-dependent modification of the phagocytic function, so that a high dose induced depression and low or long-term treatment caused a stimulation in the level of cellular activation of murine peritoneal phagocytic cells induced by zymosan and measured by CL assay. These results are contradictory with those described by Grochla et al.29) and Gnarpe et al.28\ which showed no influence on the phagocytic activity determined by CL assay, using an experimental model of in vitro I/C treatment. The reason for this discrepancy between our results and those of these authors could be attributed to the fact that they used an in vitro experimental model with a phagocytic cell population isolated from untreated-human peripheral blood, mainly polymorphonuclear cells, that were preincubated with different concentrations of I/C, whereas in our ex vivo experimental model, the population was constituted of murine peritoneal phagocytes, macrophages (75%) and polymorphonuclear cells (15%).
Moreover, the stimulatory effect of I/C on phagocytic activity of peritoneal leukocytes is in agreement with previous studies made by Nunez et al.30) route. In both cases high dose and long-term I/C ad- JUNE 1997 ministration induced a significant increase in such cellular activities, which in the case of NKactivity was very strong. Since IL-2 is known to be a potent inducer of both proliferation and citolytic activity of NKcells, the effect of the antibiotic therapy as far as increase in NK cell activity could be due to the concurrent increase in IL-2 production by T cells, which is also promoted by high dose and long-term I/C administration to mice (data not shown).
The absence of a possible toxic effect of the highest I/C concentration on these cellular activities is remarkable, as opposed to that exerted on the phagocytic function as shown previously.
The duration of treatment and dose of I/C play a decisive role in the effect on immune functions. The immune parameters analyzed in treated mice do not undergo any statistically significant modification in the presence of I/C treatment at middling doses (1 and 2g/70kg/day) during 7 days, whereas the greater I/C dose used (4g/70kg/day) has an inhibitory effect on PC counts and phagocytic activity of peritoneal leukocytes, but it causes an increase on IL-1 production and NK activity of splenic cells from treated mice. The maximal effect on the stimulation of immunesystem was obtained at the lowest I/C dose (0.5g/70kg/day) used, which is compatible with the idea that this dose causes the maximal release of active bacterial factors that has been described by us in the case of the quinolone ciprofloxacin6). Based on these investigations, imipenem/ cilastatin may be considered to be a potent broadspectrum beta-lactam antibiotic for clinical application. Since it apparently does not impair the studied innate immuneresponses, at 1 or 2g/70kg/day, it should be especially suited for the therapy of systemic bacterial infections in immunocompromised patients. However, further studies should be initiated to determine the effect of a widespread use of this broad-spectrum antibiotic on the human immuneresponses. on humoral immune response. In 
